You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel Screen Approach to Inactivate Whole Viral Vaccines by Supralethal Irradiation

    SBC: AGAVE BIOSYSTEMS INC.            Topic: DTRA14B002

    Future vaccine development should focus on rapid upscale production, long-term and broad protection, and sufficient global distribution to prevent and reduce the impact of many infectious diseases and potential epidemics. Agave BioSystems proposes to develop a novel whole-microorganism vaccine inactivation strategy involving high-throughput screen of extensive radio-protectant matrices and radiati ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  2. High-specificity affinity reagents for the detection of glycan sialylation

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Approach to Purifying iPSC Derived Cell Cultures

    SBC: HocusLocus Inc.            Topic: 200

    DESCRIPTION provided by applicant We are pioneering an RNA based switch technology called structurally interacting RNAs sxRNA which utilizes post transcriptional gene regulation as a reporter for miRNA detection Normally RNA binding proteins RBP associate with a andapos stem loop structure to facilitate translation of an upstream coding region by as much as an order of magnitude It is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    DESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a high-throughput assay for measuring m6A demethylase activity

    SBC: Base5 Biosciences Inc            Topic: NIDA

    DESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Technology-Guided Opioid Cessation for Post-Operative Pain

    SBC: MedicaSafe Inc            Topic: R41

    DESCRIPTION provided by applicant This STTR application proposes development of MedicaSafe Inc andapos s Multimodal Analgesic Protection System MAPSafe Built around MedicaSafeandapos s proprietary Medication Therapy Optimization MTO technology MAPSafe will be designed to mitigate the myriad risks associated with prescription opioid use post operatively and throughout recovery after surge ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation

    SBC: Cambium Medical Technologies LLC            Topic: N

    DESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government